ETH spin-off OBaris acquired by Johnson & Johnson
03.09.2025
Johnson & Johnson has acquired OBaris, a Swiss Biotech spin-off developing a novel drug delivery platform. With its OctoPatch® technology, OBaris aims to make oral administration possible for therapies that are usually limited to injections. As part of Johnson & Johnson, the platform will be advanced within a global healthcare ecosystem.
 |
 |
Founded as a preclinical-stage spin-off from ETH Zürich and Universitätsspital Zürich (USZ), OBaris has concentrated on solving a key challenge in medicine: improving the stability and absorption of biologics and other complex drugs when taken orally. Its approach could widen treatment options and improve convenience for patients.
By acquiring OBaris, Johnson & Johnson strengthens its focus on innovative delivery technologies. The move aligns with the company’s longstanding goal of improving health worldwide and expanding patient access to novel therapies.
OBaris participated in Venture Leaders Biotech and won Venture Kick.
OBaris Co-Founders: CTO Nevena Paunovic and CEO David Klein Cerrejon
By acquiring OBaris, Johnson & Johnson strengthens its focus on innovative delivery technologies. The move aligns with the company’s longstanding goal of improving health worldwide and expanding patient access to novel therapies.
OBaris participated in Venture Leaders Biotech and won Venture Kick.
OBaris Co-Founders: CTO Nevena Paunovic and CEO David Klein Cerrejon